RADLY:OTC-Raia Drogasil S.A (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC

Last Closing Price

USD 5.39

Change

0.00 (0.00)%

Market Cap

USD 8.89B

Volume

125.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. As of September 30, 2020, the company operated a network of 2,223 drug stores in 23 Brazilian states. It also markets its goods through telesales and its three call centers in the states of São Paulo and Tocantins. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALBHF Alibaba Health Information Tec..

N/A

USD29.27B 542.50 70.16
CLCGY Clicks Group Limited

N/A

USD4.83B 34.98 1.11
ZRSEF Zur Rose Group AG

N/A

USD4.09B N/A N/A
SDGCF Sundrug Co.,Ltd

N/A

USD3.81B 16.60 0.08
FFLWF Fire & Flower Holdings Corp

N/A

USD0.29B N/A 11.91
DRVD Driven Deliveries, Inc

N/A

USD0.06B N/A N/A
RXMD Progressive Care, Inc

N/A

USD0.03B N/A 17.28
HADV Health Advance Inc

N/A

USD0.01B N/A N/A
HEWA HealthWarehouse.com, Inc

N/A

USD8.78M 56.67 N/A
RLLVF Relevium Technologies Inc

N/A

USD2.07M N/A N/A

ETFs Containing RADLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.33% 44% F 46% F
Dividend Return 0.10% 33% F 1% F
Total Return 14.43% 31% F 45% F
Trailing 12 Months  
Capital Gain 25.35% 47% F 39% F
Dividend Return 0.51% 33% F 4% F
Total Return 25.86% 40% F 38% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.92% 29% F 47% F
Dividend Return 0.48% 33% F 20% F
Total Return 9.39% 24% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 30.62% 94% A 65% D
Risk Adjusted Return 30.67% 41% F 55% F
Market Capitalization 8.89B 94% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 84.14 29% F 9% F
Price/Book Ratio 10.14 44% F 15% F
Price / Cash Flow Ratio 6.02 31% F 26% F
EV/EBITDA 4.34 57% F 51% F
Management Effectiveness  
Return on Equity 12.67% 80% B- 78% C+
Return on Invested Capital 13.88% 60% D- 79% C+
Return on Assets 4.67% 77% C+ 82% B-
Debt to Equity Ratio 25.72% 38% F 51% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.52 41% F 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.